Direct instillation of a replication-deficient adenovirus encoding IFNα into patients with minimally invasive bladder cancer has shown anti-tumor efficacy [5] and was recently approved for use by the FDA. The gene discussed is IFNA1; the disease is urinary bladder carcinoma.